Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen - Ruszniewski, P.; Cwikla, J.; Lombard-Bohas, C.; Borbath, I.; Shah, T.; Pape, U-F.; Thanh, X-M. Truong; Houchard, A.; Pavel, Marianne Ellen (ANNALS OF ONCOLOGY, 2019)
CRIS-Team WoS Importer:2019-11-08